Novartis faces third clinical-trial setback in a week as muscle drug fails

How 1 sources are covering this

• Business StandardCenter·1h ago

  Novartis faces third clinical-trial setback in a week as muscle drug fails

  The medicine, called del-desiran, was the centerpiece of Novartis's $12 billion takeover of Avidity Biosciences and touted as a potential blockbuster

  Read at Business Standard →